Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing–Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter Study

Key Points

• Patients treated with ofatumumab exhibited improved treatment outcomes compared to those receiving ocrelizumab, highlighting potential benefits.
• The study tracked 250 patients over six months, where 75% on ofatumumab reported fewer relapses than those on ocrelizumab.
• Analysis employed inverse probability of treatment weighting to account for treatment selection bias and ensure observational validity.
• This real-world evidence may support enhanced therapeutic strategies, though further research is needed to confirm these findings.